Prognostic factors in aggressive non-Hodgkin's lymphomas
dc.contributor.author | Nikolaides, C. | en |
dc.contributor.author | Dimou, S. | en |
dc.contributor.author | Pavlidis, Nicholas | en |
dc.creator | Nikolaides, C. | en |
dc.creator | Dimou, S. | en |
dc.creator | Pavlidis, Nicholas | en |
dc.date.accessioned | 2018-06-22T09:54:08Z | |
dc.date.available | 2018-06-22T09:54:08Z | |
dc.date.issued | 1998 | |
dc.identifier.uri | https://gnosis.library.ucy.ac.cy/handle/7/42203 | |
dc.description.abstract | Aggressive non-Hodgkin's lymphoma (NHL) is a biologically heterogeneous disease that can be cured with aggressive chemotherapy treatment. Different clinical, biological, cellular and molecular features have been identified as having prognostic significance on the outcome of NHL patients. The knowledge of these prognostic features can be used in everyday practice in order to predict the prognosis of every new NHL patient and tailor his or her treatment accordingly. | en |
dc.language.iso | eng | en |
dc.source | Oncologist | en |
dc.subject | Age | en |
dc.subject | Article | en |
dc.subject | Antineoplastic agent | en |
dc.subject | Bleomycin | en |
dc.subject | Cyclophosphamide | en |
dc.subject | Cytarabine | en |
dc.subject | Doxorubicin | en |
dc.subject | Etoposide | en |
dc.subject | Human | en |
dc.subject | Methotrexate | en |
dc.subject | Prednisone | en |
dc.subject | Vincristine | en |
dc.subject | Adult | en |
dc.subject | Aged | en |
dc.subject | Cancer combination chemotherapy | en |
dc.subject | Cancer survival | en |
dc.subject | Priority journal | en |
dc.subject | Prognosis | en |
dc.subject | Dexamethasone | en |
dc.subject | Treatment outcome | en |
dc.subject | Nonhodgkin lymphoma | en |
dc.subject | Folinic acid | en |
dc.subject | Protein bcl 2 | en |
dc.subject | Protein p53 | en |
dc.subject | Prognostic factors | en |
dc.subject | Immune response | en |
dc.subject | Cytokine | en |
dc.subject | Gene mutation | en |
dc.subject | Hemoglobin | en |
dc.subject | Albumin | en |
dc.subject | Tumor suppressor gene | en |
dc.subject | Chromosome deletion | en |
dc.subject | Chromosome translocation | en |
dc.subject | Erythrocyte sedimentation rate | en |
dc.subject | Glycoprotein p | en |
dc.subject | Human immunodeficiency virus infection | en |
dc.subject | Non-hodgkin's lymphoma | en |
dc.subject | Protein bax | en |
dc.title | Prognostic factors in aggressive non-Hodgkin's lymphomas | en |
dc.type | info:eu-repo/semantics/article | |
dc.description.volume | 3 | |
dc.description.issue | 3 | |
dc.description.startingpage | 189 | |
dc.description.endingpage | 197 | |
dc.author.faculty | Ιατρική Σχολή / Medical School | |
dc.author.department | Ιατρική Σχολή / Medical School | |
dc.type.uhtype | Article | en |
dc.contributor.orcid | Pavlidis, Nicholas [0000-0002-2195-9961] | |
dc.gnosis.orcid | 0000-0002-2195-9961 |
Files in this item
Files | Size | Format | View |
---|---|---|---|
There are no files associated with this item. |